Hagens Berman & Illumina — Holy Grail

Hagens Berman: Hagens Berman filed a class action and is conducting an investigation into when Illumina — Holy Grail management knew the trial timeline was insufficient. The firm is urging investors with losses to contact them before the lead plaintiff deadline.

Illumina — Holy Grail: Illumina — Holy Grail is the defendant in multiple securities fraud class actions. The company's stock collapsed 50.55% after its NHS-Galleri trial failed to meet its primary endpoint, erasing over $2.2 billion in market capitalization. The litigation and trial failure severely damage its financial standing and investor trust.

Hagens Berman: Hagens Berman is one of the law firms that filed the class action lawsuit against Illumina — Holy Grail, representing investors.

Illumina — Holy Grail: Illumina — Holy Grail is the defendant in the securities class action; its stock dropped over 50% after the NHS-Galleri trial failed to meet its primary endpoint, resulting in a $2.2 billion market cap loss.